• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Lillys Bad Bet

Anonymous

Guest
Lilly doubled down on beta amyloid researchers found it to be tau not beta amyloid. The good Dr. Lechlieter is not a good businessman or scientist, but he's a great opportunist, huge bank account for outstanding performance.